Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia

Launched by UNIVERSITY COLLEGE, LONDON · Mar 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called sarcopenia, which is the loss of muscle mass and strength that often happens as we age. This condition is particularly common in older adults with chronic lung diseases, such as COPD or interstitial lung disease. Sarcopenia can make it harder for these individuals to move around and enjoy life, and it can also lead to other health problems. The study aims to see how well a new approach called FACS (finding, assessing, confirming, severity) works in identifying how many people with chronic lung disease have sarcopenia. The FACS approach involves simple tests to measure strength and body composition.

To participate in this study, you need to be an adult (18 years or older) diagnosed with a chronic lung disease, and you must be able to give informed consent. However, if you have serious other health issues that could affect your muscles, or if you have recently undergone major treatments or surgeries, you may not be eligible. If you join the study, you can expect to undergo some tests that check your muscle strength and health, and your experience will help researchers understand how to conduct future studies better. The trial is not yet recruiting participants, but it will provide important information that could lead to new ways to help improve the quality of life for those affected by sarcopenia and chronic lung disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients diagnosed with chronic lung disease (≥ 18years).
• • 2. Only patients who are willing and able to provide informed consent to participate in the study.
• Exclusion Criteria:
• • 1. Patients with other major comorbidities that could significantly impact muscle mass and function, such as severe heart failure, advanced liver or kidney disease, uncontrolled diabetes, or malignancies.
• • 2. Patients with acute exacerbations of their chronic lung disease or any other acute illness at the time of the study. 3. Patients with a history of neuromuscular disorders or disability that could significantly affect muscle mass and function.
• • 4. Patients who have undergone recent surgery in the past 6 months or have received specific treatments that could influence muscle mass and function, such as long-term corticosteroid use, chemotherapy, or radiation therapy.
• • 5. Patients with life expectancy of less than 6 months 6. Patients who are unable or unwilling to comply with the study protocol or procedures.
• • 7. Patients that are unable to give informed consent.